SCHEMBL4545404

SCHEMBL4545404

O=C(Cc1ccc(O)c(Cl)c1)ON1C(=O)CCC1=O

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CA2 P00918 9/20 0.54
CA1 P00915 7/20 0.46
HSD17B2 P37059 3/20 0.44
SIGMAR1 Q99720 3/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
TSHR P16473 1/20 0.41
PIK3CA P42336 2/20 0.40
ALDH1A1 P00352 2/20 0.39
YWHAG P61981 1/20 0.39
GAA P10253 1/20 0.39
GFER P55789 1/20 0.39
KDM4E B2RXH2 1/20 0.39
BLM P54132 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31225941 1.00 CA2 (0.54) CA2CA1HSD17B2SIGMAR1CYP1A2
SCHEMBL31225825 0.89 SIGMAR1 (0.41) CA2SIGMAR1CYP1A2CYP2D6TSHR
SCHEMBL22046620 0.86 BACE1 (0.45) CA2CA1ALDH1A1
SCHEMBL18790062 0.82 CA2 (0.45) CA2CA1HSD17B2SIGMAR1CYP1A2
SCHEMBL31225832 0.82 SIGMAR1 (0.40) SIGMAR1CYP1A2CYP2D6TSHRALDH1A1
SCHEMBL499428 0.81 KMT2A (0.46) TSHRALDH1A1
SCHEMBL7522573 0.81 TSHR (0.58) HSD17B2TSHRALDH1A1GAA
SCHEMBL9465229 0.80 MGLL (0.48) TSHRALDH1A1KDM4E
SCHEMBL13702252 0.79 POLB (0.43) CA2CA1TSHRALDH1A1KDM4E
SCHEMBL31225767 0.79 P2RX7 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF ADAXION THERAPEUTICS, INC. 2025-02-27 US disclosed
US-20190247388-A1 OLIGOMER-OPIOID AGONIST CONJUGATES NEKTAR THERAPEUTICS 2019-08-15 US disclosed
US-10307416-B2 Oligomer-opioid agonist conjugates NEKTAR THERAPEUTICS (US) 2019-06-04 US disclosed
US-20190046523-A1 OLIGOMER-OPIOID AGONIST CONJUGATES NEKTAR THERAPEUTICS 2019-02-14 US disclosed
US-9827239-B2 Oligomer-opioid agonist conjugates NEKTAR THERAPEUTICS (US) 2017-11-28 US disclosed
US-9827239-B2 Oligomer-opioid agonist conjugates NEKTAR THERAPEUTICS (US) 2017-11-28 US disclosed
EP-3222293-A1 OLIGOMER-OPIOID AGONIST CONJUGATES Nektar Therapeutics (US) 2017-09-27 EP disclosed
EP-2620163-B1 OLIGOMER-OPIOID AGONIST CONJUGATES NEKTAR THERAPEUTICS (US) 2017-05-03 EP disclosed
US-20170112826-A1 OLIGOMER-OPIOID AGONIST CONJUGATES NEKTAR THERAPEUTICS 2017-04-27 US disclosed
US-20170112826-A1 OLIGOMER-OPIOID AGONIST CONJUGATES NEKTAR THERAPEUTICS 2017-04-27 US disclosed
US-20120289548-A1 OLIGOMER-OPIOID AGONIST CONJUGATES NEKTAR THERAPEUTICS (US) 2012-11-15 US disclosed
US-20120264775-A1 Oligomer-Opioid Agonist Conjugates NEKTAR THERAPEUTICS (US) 2012-10-18 US disclosed
US-20120264775-A1 Oligomer-Opioid Agonist Conjugates NEKTAR THERAPEUTICS (US) 2012-10-18 US disclosed
US-20120184581-A1 Oligomer-Opioid Agonist Conjugates NEKTAR THERAPEUTICS (US) 2012-07-19 US disclosed
US-20120184581-A1 Oligomer-Opioid Agonist Conjugates NEKTAR THERAPEUTICS (US) 2012-07-19 US disclosed
US-8173666-B2 Oligomer-opioid agonist conjugates NEKTAR THERAPEUTICS (US) 2012-05-08 US disclosed
US-8173666-B2 Oligomer-opioid agonist conjugates NEKTAR THERAPEUTICS (US) 2012-05-08 US disclosed
US-20100048602-A1 Oligomer-Opioid Agonist Conjugates NEKTAR THERAPEUTICS (US) 2010-02-25 US disclosed
US-20100048602-A1 Oligomer-Opioid Agonist Conjugates NEKTAR THERAPEUTICS (US) 2010-02-25 US disclosed
WO-2008112288-A2 OLIGOMER-OPIOID AGONIST CONJUGATES NEKTAR THERAPEUTICS (US) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170112826-A1 OLIGOMER-OPIOID AGONIST CONJUGATES OPRM1, OPRL1, OPRK1 CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885
US-10307416-B2 Oligomer-opioid agonist conjugates OPRM1, OPRL1, OPRK1 CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885
US-20190046523-A1 OLIGOMER-OPIOID AGONIST CONJUGATES OPRM1, OPRL1, OPRK1 CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885
US-20190247388-A1 OLIGOMER-OPIOID AGONIST CONJUGATES OPRM1, OPRL1, OPRK1 CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF SIGLEC7, SIGLEC9, CD2BP2 CA2 3330/4885CA1 669/4885HSD17B2 4172/4885
US-20120184581-A1 Oligomer-Opioid Agonist Conjugates OPRM1, OPRL1, OPRK1 CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885
US-20100048602-A1 Oligomer-Opioid Agonist Conjugates OPRM1, OPRL1, OPRK1 CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885
US-20120289548-A1 OLIGOMER-OPIOID AGONIST CONJUGATES OPRM1, OPRL1, OPRK1 CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885
US-20120264775-A1 Oligomer-Opioid Agonist Conjugates OPRM1, OPRL1, OPRK1 CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.